156 related articles for article (PubMed ID: 32211268)
1. Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status.
Pereira J; Alves F; Ferreira F; Vasconcelos de Matos L; Massena A; Martins A
Cureus; 2020 Feb; 12(2):e7035. PubMed ID: 32211268
[TBL] [Abstract][Full Text] [Related]
2. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic.
Ghatalia P; Smith CH; Winer A; Gou J; Kiedrowski LA; Slifker M; Saltzberg PD; Bubes N; Anari FM; Kasireddy V; Varshavsky A; Liu Y; Ross EA; El-Deiry WS
Front Oncol; 2018; 8():652. PubMed ID: 30705875
[No Abstract] [Full Text] [Related]
4. Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
Albuquerque J; Neto da Silva D; Padrão T; Leal-Costa L; Bizarro R; Correia J; Baptista C; Machete M; Prazeres G; Margarido I; Fernandes G; Simões P; Timóteo T; Lopes F; Godinho J; Moreira-Pinto J; Rodrigues T; Faria A; Pulido C; Cirnes L; Teixeira JA; Passos Coelho JL
Oncologist; 2024 Mar; 29(3):e337-e344. PubMed ID: 38071748
[TBL] [Abstract][Full Text] [Related]
5. Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Germani MM; Vetere G; Giordano M; Ciracì P; Capone I; Tamborini E; Conca E; Busico A; Pietrantonio F; Piva VM; Boccaccino A; Simionato F; Bortolot M; Manca P; Lonardi S; Conca V; Borelli B; Carullo M; Del Re M; Fontanini G; Rossini D; Cremolini C
Front Oncol; 2023; 13():1307545. PubMed ID: 38406172
[TBL] [Abstract][Full Text] [Related]
6. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
Archwamety A; Teeyapun N; Siripoon T; Poungvarin N; Tanasanvimon S; Sirachainan E; Akewanlop C; Korphaisarn K
Front Oncol; 2022; 12():813009. PubMed ID: 35242708
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
[TBL] [Abstract][Full Text] [Related]
8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
10. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis.
Lin LI; Chen LL; Wang Y; Meng XY; Liang C; Zhou FX
Mol Clin Oncol; 2016 Jun; 4(6):1017-1024. PubMed ID: 27284437
[TBL] [Abstract][Full Text] [Related]
12. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract][Full Text] [Related]
15. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
16. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
17. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
19. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.
Valladares-Ayerbes M; Safont MJ; González Flores E; García-Alfonso P; Aranda E; Muñoz AL; Falcó Ferrer E; Cirera Nogueras L; Rodríguez-Salas N; Aparicio J; Llanos Muñoz M; Pimentel Cáceres PP; Castillo Trujillo OA; Vidal Tocino R; Salgado Fernández M; Salud-Salvia A; Massuti Sureda B; Garcia-Carbonero R; Vicente Conesa MÁ; Lloansí Vila A;
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38642257
[TBL] [Abstract][Full Text] [Related]
20. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]